Literature DB >> 17044551

Results of attempted radical tumor removal and venous repair in 100 consecutive meningiomas involving the major dural sinuses.

Marc P Sindou1, Jorge E Alvernia.   

Abstract

OBJECT: Radical removal of meningiomas involving the major dural sinuses remains controversial. In particular, whether the fragment invading the sinus must be resected and whether the venous system must be reconstructed continue to be issues of debate. In this paper the authors studied the effects, in terms of tumor recurrence rate as well as morbidity and mortality rates, of complete lesion removal including the invaded portion of the sinus and the consequences of restoring or not restoring the venous circulation.
METHODS: The study consisted of 100 consecutive patients who had undergone surgery for meningiomas originating at the superior sagittal sinus in 92, the transverse sinus in five, and the confluence of sinuses in three. A simplified classification scheme based on the degree of sinus involvement was applied: Type I, lesion attachment to the outer surface of the sinus wall; Type II, tumor fragment inside the lateral recess; Type III, invasion of the ipsilateral wall; Type IV, invasion of the lateral wall and roof; and Types V and VI, complete sinus occlusion with or without one wall free, respectively. Lesions with Type I invasion were treated by peeling the outer layer of the sinus wall. In cases of sinus invasion Types II to VI, two strategies were used: a nonreconstructive (coagulation of the residual fragment or global resection) and a reconstructive one (suture, patch, or bypass). Gross-total tumor removal was achieved in 93% of cases, and sinus reconstruction was attempted in 45 (65%) of the 69 cases with wall and lumen invasion. The recurrence rate in the study overall was 4%, with a follow-up period from 3 to 23 years (mean 8 years). The mortality rate was 3%, all cases due to brain swelling after en bloc resection of a Type VI meningioma without venous restoration. Eight patients--seven of whom harbored a lesion in the middle third portion of the superior sagittal sinus--had permanent neurological aggravation, likely due to local venous infarction. Six of these patients had not undergone a venous repair procedure.
CONCLUSIONS: The relatively low recurrence rate in the present study (4%) favors attempts at complete tumor removal, including the portion invading the sinus. The subgroup of patients without venous reconstruction displayed statistically significant clinical deterioration after surgery compared with the other subgroups (p = 0.02). According to this result, venous flow restoration seems justified when not too risky.

Entities:  

Mesh:

Year:  2006        PMID: 17044551     DOI: 10.3171/jns.2006.105.4.514

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  27 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

2.  Meningiomas: skull base versus non-skull base.

Authors:  Torstein R Meling; Michele Da Broi; David Scheie; Eirik Helseth
Journal:  Neurosurg Rev       Date:  2018-04-07       Impact factor: 3.042

3.  Transient neurologic deterioration after total removal of parasagittal meningioma including completely occluding superior sagittal sinus.

Authors:  In Ho Oh; Bong Jin Park; Seok Keun Choi; Young Jin Lim
Journal:  J Korean Neurosurg Soc       Date:  2009-07-31

4.  Long-term outcome in meningiomas involving the major dural sinuses with combined therapy of subtotal resection and early postoperative gamma knife radiosurgery.

Authors:  Peng Lv; Jia-Jing Wang; Nan-Xiang Xiong; Xiao-Ming Liu; Dong-Xiao Yao; Xiao-Bing Jiang; Hong-Yang Zhao; Fang-Cheng Zhang; Peng Fu
Journal:  Acta Neurochir (Wien)       Date:  2021-02-20       Impact factor: 2.216

Review 5.  Resection of falx and parasagittal meningioma: complication avoidance.

Authors:  Stephen T Magill; Philip V Theodosopoulos; Michael W McDermott
Journal:  J Neurooncol       Date:  2016-10-24       Impact factor: 4.130

6.  Intracranial hypertension due to meningioma of the unique transverse sinus.

Authors:  G Mariniello; A Giamundo; R Donzelli; R Severino; C Russo; A Elefante; F Maiuri
Journal:  Neuroradiol J       Date:  2013-05-10

7.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

8.  Diploic veins as collateral venous pathways in patients with dural venous sinus invasion by meningiomas.

Authors:  Kei Yamashiro; Jun Muto; Akira Wakako; Kazuhiro Murayama; Daijiro Kojima; Tatsuo Omi; Kazuhide Adachi; Mitsuhiro Hasegawa; Yuichi Hirose
Journal:  Acta Neurochir (Wien)       Date:  2021-02-24       Impact factor: 2.216

9.  Long-term outcomes of multimodality management for parasagittal meningiomas.

Authors:  Lingyang Hua; Daijun Wang; Hongda Zhu; Jiaojiao Deng; Shihai Luan; Haixia Chen; Shuchen Sun; Hailiang Tang; Qing Xie; Hiroaki Wakimoto; Ye Gong
Journal:  J Neurooncol       Date:  2020-02-22       Impact factor: 4.130

Review 10.  STA-MCA Bypass in Carotid Stenosis after Radiosurgery for Cavernous Sinus Meningioma.

Authors:  Marco Vincenzo Corniola; Marton König; Torstein Ragnar Meling
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.